FY2029 Earnings Estimate for TRVI Issued By B. Riley

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at B. Riley issued their FY2029 earnings per share estimates for shares of Trevi Therapeutics in a note issued to investors on Thursday, February 13th. B. Riley analyst M. Mamtani expects that the company will post earnings of ($0.95) per share for the year. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. B. Riley also issued estimates for Trevi Therapeutics' FY2029 earnings at ($0.95) EPS.

Several other research analysts have also issued reports on the company. HC Wainwright upped their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the company a "buy" rating in a research report on Thursday, December 12th. D. Boral Capital reaffirmed a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 target price on shares of Trevi Therapeutics in a research report on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $9.31.

Trevi Therapeutics Trading Up 8.3 %

Shares of TRVI traded up $0.35 during trading hours on Monday, hitting $4.57. The company had a trading volume of 848,828 shares, compared to its average volume of 532,788. The company's fifty day moving average price is $4.02 and its two-hundred day moving average price is $3.36. Trevi Therapeutics has a one year low of $2.30 and a one year high of $4.68. The company has a market capitalization of $351.30 million, a PE ratio of -10.39 and a beta of 0.88.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TRVI. Summit Investment Advisors Inc. increased its holdings in shares of Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after purchasing an additional 2,894 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock valued at $40,000 after purchasing an additional 6,764 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Trevi Therapeutics in the fourth quarter valued at about $49,000. Squarepoint Ops LLC acquired a new position in shares of Trevi Therapeutics in the fourth quarter valued at about $58,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Trevi Therapeutics in the third quarter worth about $63,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.